Search Results

DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

DisperSol Technologies, LLC, a specialty pharmaceutical company, today announced the appointment of Tim Scott as president and chief executive officer (CEO) of the company.

DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.

DisperSol Technologies LLC announced today that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies.

DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug development and review process, particularly for rare diseases.

DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar

Later this month, HHS Secretary Robert F. Kennedy Jr.'s revamped CDC vaccine advisory committee will discuss RSV vaccination guidelines for the newly approved patient group, high-risk adults 18 through 49. Analysts and other experts have warned that the new panel includes some who have documented anti-vaccine sentiments as well as those who have spoken out against mRNA technology specifically.